AIM: This study aimed to assess the cost-effectiveness of starting insulin therapy with biphasic insulin aspart 30 ( @entity14184 ) in @entity1 with type 2 @entity6 inadequately controlled on oral @entity413 -lowering drugs in Saudi Arabia, India, Indonesia, and Algeria. METHODS: The IMS CORE @entity6 Model was used to evaluate economic outcomes associated with starting @entity14184 , using baseline characteristics and treatment outcomes from the A1chieve study. Time horizons of 1 and 30 years were applied, with country-specific costs for complications, therapies, and background mortality. Incremental cost-effectiveness ratios (ICERs) are expressed as cost per quality-adjusted life-year (QALY) in local currencies, USD, and fractions of local @entity3006 per capita (GDPc). Cost-effectiveness was pre-defined using the World Health Organization definition of <3.0 times GDPc. Comprehensive sensitivity analyses were performed. RESULTS: In the primary 30-year analyses, starting @entity14184 was associated with a projected increase in life expectancy of >1 year and was highly cost-effective, with ICERs of -0.03 (Saudi Arabia), 0.25 (India), 0.48 (India), 0.47 (Indonesia), and 0.46 (Algeria) GDPc/QALY. The relative risk of developing selected complications was reduced in all countries. Sensitivity analyses including cost of self-monitoring, treatment costs, and deterioration of @entity413 control with time showed the results to be robust. In a 1-year analysis, @entity10679 per QALY gained was still cost-effective or highly cost-effective. CONCLUSION: Starting @entity14184 in @entity1 with type 2 @entity6 in the A1chieve study was found to be cost-effective across all country settings at 1- and 30-year time horizons, and usefully increased predicted life expectancy.

An analysis of the short- and long-term cost-effectiveness of starting biphasic insulin aspart 30 in insulin-na  ve XXXX with poorly controlled type 2 @entity6 .

@entity1 :: ('9606', 'Species') :: ['people'] @entity14184 :: ('MESH:C557564', 'Chemical') :: ['BIAsp 30'] @entity6 :: ('MESH:D003920', 'Disease') :: ['Diabetes', 'diabetes'] @entity3006 :: ('MESH:D006153', 'Chemical') :: ['GDP'] @entity10679 :: ('1390', 'Gene') :: ['ICER'] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']
@entity1 :: (9606,Species) :: ['people']
